GlassScriptPhysician profile
Nayeema Ahmed
NPI 1063410280
$2,780.21
in general payments reported to CMS, 2019-2025
30 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $257 · 2021: $897 · 2022: $387 · 2023: $198 · 2024: $398 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $793.90 | 2019-2022 | |
| Hologic Sales and Service, LLC | $254.21 | 2022-2025 | Omni Hysteroscope, Aptima, Novasure |
| Evofem Biosciences, INC. | $243.16 | 2021-2025 | Solosec, Phexx, Phexxi |
| Aspira Women'S Health INC | $212.18 | 2019-2024 | Ova1 |
| Myovant Sciences INC. | $127.75 | 2021-2022 | |
| Organon LLC | $114.12 | 2021-2025 | Nexplanon |
| Pfizer INC. | $112.96 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $112.60 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $87.11 | 2021 | |
| Merck Sharp & Dohme LLC | $76.47 | 2019-2024 | Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $68.66 | 2024 | Invega Sustenna, Invega Trinza |
| Davol INC. | $62.26 | 2020 | |
| Ethicon US, LLC | $52.73 | 2020-2021 | |
| Roche Diagnostics Corporation | $49.42 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.23 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $44.63 | 2024-2025 | Slynd |
| Novo Nordisk INC | $36.50 | 2022-2025 | |
| Becton, Dickinson and Company | $31.63 | 2024 | Arista Ah Flexitip |
| Astellas Pharma US INC | $27.86 | 2024 | Veozah |
| Cumberland Pharmaceuticals, INC. | $26.04 | 2021-2023 | Kristalose |
| Biom'Up France Sas | $24.85 | 2021 | |
| Therapeuticsmd, INC. | $23.69 | 2021 | |
| Amag Pharmaceuticals, INC. | $23.37 | 2019 | |
| Applied Medical Resources Corporation | $22.92 | 2023 | |
| Avanos Medical | $21.00 | 2019 | |
| Millicent US INC | $20.17 | 2025 | Femlyv |
| Agile Therapeutics, INC. | $19.21 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.89 | 2021 | |
| Shield Therapeutics INC | $13.36 | 2023 | Accrufer |
| Allergan, INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayeema Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.